DataMEDS AI, Inc. (MEDS) |
| 2.63 -0.22 (-7.72%) 10-16 16:00 |
| Open: | 2.8 |
| High: | 2.86 |
| Low: | 2.6201 |
| Volume: | 286,404 |
| Market Cap: | 7(M) |
| PE Ratio: | 0 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Medical - Distribution |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 12.31 |
| Resistance 1: | 7.94 |
| Pivot price: | 3.23 |
| Support 1: | 0.86 |
| Support 2: | 0.72 |
| 52w High: | 73 |
| 52w Low: | 0.8225 |
DataMEDS AI is a Health IT company focused on the vertical integration of technology, pharmacy, pharmaceutical-adjacent, and telemedicine business units. The company incorporates its artificial intelligence platform EinsteinRx™ and blockchain-enabled smart contacts platform PharmacyChain™ to optimize the prescription medicines reimbursement and dispensing journey.
| EPS | -46.680 |
| Book Value | -6.880 |
| PEG Ratio | 0.00 |
| Gross Profit | -2.569 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | -412.68 |
| Return on Assets (ttm) | -82.9 |
| Return on Equity (ttm) | 0.0 |
Fri, 16 Oct 2026
A consumer weight-management license could require extra shares from DataMeds AI (Nasdaq: MEDS). - Stock Titan
Fri, 16 Oct 2026
DataMeds Applauds FDA's Proposed Interim Access Policy for Compounding Using Certain Peptides and Provides Corexa Health's Peptides Roadmap - Kitsap Sun
Fri, 16 Oct 2026
DataMEDS AI, Inc. (MEDS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Fri, 16 Oct 2026
DataMeds AI Plans Peptide Compounding Expansion Through Corexa Health Following FDA Policy Proposal - Yahoo Finance
Fri, 16 Oct 2026
DataMeds AI, Inc. (MEDS) Maps Strategy for FDA’s Proposed Peptide Policy - TradingView
Wed, 14 Oct 2026
DataMEDS Si Licenses U.S. Rights To Reboot Health AI’s Direct-To-Consumer GLP-1 Weight Management Platform - The Globe and Mail
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |